NaV1.8 Inhibitors Market By Product (Suzetrigine/Journavx, LTG-001, LTG-305, STC-004, VX-993, Grünenthal NaV1.8 Inhibitor, Other Investigational NaV1.8 Inhibitors), By Application (Moderate-to-Severe Acute Pain, Postoperative Pain, Painful Diabetic Peripheral Neuropathy, Other Chronic Peripheral Neuropathic Pain), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Pain Clinics, Academic and Clinical Research Institutions), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

NaV1.8 Inhibitors Market: A New Non-Opioid Pain Treatment Class Enters Commercial Healthcare

The Global NaV1.8 Inhibitors Market was valued at USD 0.06 billion in 2025 and is projected to reach USD 2.35 billion by 2032, expanding at a CAGR of  68.4% during 2026–2032, according to internal projections by Strategic Market Research.

The NaV1.8 inhibitors market entered commercial healthcare on January 30, 2025, when the U.S. Food and Drug Administration approved Vertex Pharmaceuticals’ Journavx, also known as suzetrigine, for moderate-to-severe acute pain in adults. Suzetrigine is the first and only FDA-approved medicine in this class. Its approval introduced a new prescription option for patients who need stronger pain relief but want to avoid opioids or cannot use them safely.

 

A New Pain Treatment Option Without the Opioid Pathway

NaV1.8 inhibitors are designed to reduce pain signals in nerves outside the brain and spinal cord. Suzetrigine acts on pain-sensing nerves before the signal reaches the central nervous system. This gives the class a clear commercial advantage: it can reduce pain without working through the same brain pathways as opioids.

That distinction matters because opioids can cause euphoria, breathing problems, dependence, and misuse. Journavx is not a controlled substance, and its approval created an option for hospitals and doctors seeking to reduce opioid use. It also avoids the sedation commonly associated with some older pain medicines.

The treatment is not free from limitations. Journavx has restrictions related to certain drug combinations and serious liver problems. It is also intended for short-term acute pain and has not been studied beyond 14 days of use. These conditions keep the current opportunity focused on surgery, injuries, and other short-duration pain episodes rather than long-term pain treatment.

 

Clinical Evidence Supports Selective Use Rather Than Full Opioid Replacement

FDA approval was based on two large Phase 3 studies involving adults with pain after abdominoplasty and bunion surgery. The abdominoplasty study included 1,118 participants, while the bunionectomy study included 1,073. Suzetrigine reduced pain significantly more than placebo in both studies.

The medicine produced pain relief broadly similar to hydrocodone combined with acetaminophen, but it did not prove better than that opioid combination. This result shapes its market position. Journavx is best viewed as an opioid-sparing option rather than a complete replacement for opioids in every patient.

Hospitals are likely to use it first in patients with a higher risk of opioid complications, people who prefer a non-opioid treatment, and patients treated within pain-control plans that use several medicines together. It may also be attractive after procedures where doctors want to avoid sending patients home with an opioid prescription.

Price will influence wider use. Common pain medicines such as acetaminophen, anti-inflammatory drugs, and generic opioids cost much less. Doctors and insurers will therefore assess whether the lower risk of opioid-related harm justifies the additional cost of a branded medicine.

 

Continued Opioid Use Creates a Large Policy and Treatment Gap

Demand for non-opioid pain medicines remains strong even though opioid prescribing has declined in the United States. Around 125 million opioid prescriptions were dispensed in 2023. The national retail opioid prescribing rate fell from 46.8 prescriptions per 100 people in 2019 to 35.4 in 2024.

Large differences remain between states. Arkansas recorded 68.8 opioid prescriptions per 100 people in 2024, Alabama 68.5, Mississippi 61.4, and Louisiana 59.2. These figures do not represent a direct patient pool for Journavx because many prescriptions fall outside its approved use. They do show that opioid exposure remains high in several parts of the country.

Hospitals, insurers, and public health agencies in these markets may place greater emphasis on non-opioid options. The commercial opportunity will depend on whether this policy interest results in actual changes to hospital protocols, discharge prescriptions, and insurance coverage.

 

Journavx Launch Creates the First Revenue Stream

Journavx became available in U.S. pharmacies in March 2025. Vertex reported USD 59.6 million in full-year 2025 revenue, including USD 26.7 million in the fourth quarter. More than 550,000 prescriptions were written and filled during the year across hospital and retail settings.

Insurance access expanded quickly. By January 2026, all three major U.S. pharmacy benefit managers provided access, more than 200 million people were covered, and 21 state Medicaid programs included the medicine. This gave Vertex a broad base from which to build physician use.

Hospital access also increased. More than 100 of Vertex’s 150 priority health systems and over 950 of its 2,000 targeted hospitals had added Journavx to formularies, treatment protocols, or electronic order systems by early 2026. These placements are important because pain medicines are often selected before a patient leaves the hospital.

First-quarter 2026 revenue reached USD 29 million. More than 350,000 prescriptions were filled during the quarter, total prescriptions since launch passed one million, and insurance access increased to about 240 million covered lives. The product was being used in both hospitals and retail pharmacies, showing that demand was not limited to one channel.

Revenue growth remains lower than the size of the pain population might suggest. Patients generally use Journavx for only a short period, and low-cost generic medicines remain widely available. Prescription growth will therefore depend on wider hospital use, stronger insurer support, and greater physician confidence.

 

Pricing and Reimbursement Will Shape Adoption

The announced U.S. price for a one-week Journavx course was approximately USD 232.50. This creates a clear challenge when hospitals and insurers compare it with inexpensive generic pain medicines.

The economic case depends partly on whether avoiding opioids reduces later costs linked to misuse, dependence, breathing problems, emergency treatment, or prolonged recovery. These benefits may be important, but they are not always captured by the organisation paying for the medicine. A hospital may pay more for the drug today while the long-term savings appear elsewhere in the healthcare system.

Federal payment policy improved the situation in 2026. Medicare introduced a separate payment code for suzetrigine in qualifying hospital outpatient and ambulatory surgery settings. The code became effective on January 23, 2026. This can reduce the risk that hospitals must absorb the full cost of the medicine within a fixed surgical payment.

Coverage still varies by insurer and patient. State programs may require proof of moderate-to-severe acute pain, review of other medicines, and limits on treatment length. Minnesota Medicaid, for example, allows a maximum 14-day course and applies restrictions before approval. Such controls keep use focused on clearly documented acute pain rather than routine substitution for cheaper medicines.

 

Chronic Pain Could Become the Largest Commercial Expansion

The most important future opportunity is chronic peripheral nerve pain. A short acute-pain course creates limited revenue from each patient, while chronic treatment could lead to repeated prescriptions over many months.

Painful diabetic peripheral neuropathy is the most advanced expansion target. Vertex is conducting two Phase 3 studies of suzetrigine in this condition and expected both studies to complete enrolment by the end of 2026. The company has estimated that around 2.5 million people in the United States have painful diabetic peripheral neuropathy relevant to its development program.

This estimate does not mean all 2.5 million people would receive the medicine. Actual use would depend on diagnosis, previous treatment, insurance rules, safety, price, and patient response. Even a limited share of this population could create a larger revenue opportunity than short-course acute pain.

A successful chronic-pain approval would also expand the prescriber base. Current use is concentrated among surgeons, emergency doctors, and other acute-care clinicians. Chronic use would bring neurologists, diabetes specialists, pain physicians, and primary-care doctors into the market.

The evidence standard will be higher. Long-term treatment must show sustained pain relief, acceptable safety, and value compared with established generic medicines. Insurers may also require patients to try lower-cost treatments first.

 

Competition Is Growing Beyond Vertex

Vertex remains the commercial leader, but several companies are developing competing NaV1.8 inhibitors. Not every program has succeeded. Vertex stopped developing VX-993 as a stand-alone acute-pain treatment after a Phase 2 study in bunion surgery failed to meet its main goal. The company continues to study the medicine in diabetic peripheral neuropathy.

Latigo Biotherapeutics is developing LTG-001 for acute pain and LTG-305 for chronic pain. LTG-001 received FDA Fast Track designation in March 2025 after an early study in 72 healthy participants. Latigo raised USD 150 million in Series B financing to support its pain pipeline. The separate acute and chronic programs reduce the company’s reliance on one medicine.

Eli Lilly entered the market through its planned acquisition of SiteOne Therapeutics for up to USD 1.0 billion, including upfront and milestone payments. The transaction included STC-004, a NaV1.8 inhibitor ready for Phase 2 development. Lilly’s global scale gives the program access to stronger development, reimbursement, and commercial resources.

Grünenthal also moved into human testing in February 2026 with an oral NaV1.8 inhibitor. Its Phase 1 study includes 70 healthy volunteers. The program adds another Europe-based competitor and shows that interest in the class is spreading beyond U.S. biotechnology companies.

Older compounds such as A-803467, A-887826, VX-150, and other research programs helped prove that the target could influence pain. They did not become approved medicines, but they provided knowledge that supported the development of newer candidates.

 

Regional Analysis

North America leads the NaV1.8 inhibitors market because the United States is the only country with a confirmed approval and measurable sales. FDA approval, broad insurance coverage, hospital adoption, opioid-reduction policies, and Medicare support have created the strongest commercial environment.

The United States will remain the main revenue source in the near term. Vertex’s prescription growth, more than one million cumulative prescriptions by the first quarter of 2026, and access for about 240 million covered lives give the country a clear lead.

Canada is the nearest international expansion market. Vertex planned a Canadian filing during the first half of 2026, but no confirmed approval or commercial sales were identified in the reviewed public evidence by July 2026.

Europe remains a future access market rather than a current revenue contributor. Grünenthal’s Phase 1 program shows regional research interest, but no approved NaV1.8 inhibitor was identified. European adoption will depend on regulatory approval, national price negotiations, and evidence that a branded medicine provides enough value over cheap standard treatments.

 

Market Outlook, 2026–2032

The market is likely to develop in two phases. The first phase will be continued U.S. growth in acute pain through more hospital protocols, wider physician use, stronger pharmacy availability, and reimbursement support. Prescription volume will be more important than broad pain-population estimates because each patient receives only a short course.

The second phase depends on chronic-pain approvals. Positive Phase 3 results in painful diabetic peripheral neuropathy could change the market from short treatment episodes to recurring prescriptions. This would increase revenue per patient and expand the number of doctors able to prescribe the class.

Competition will also influence market growth. Latigo, Lilly, Grünenthal, and other developers will try to improve on Journavx through faster onset, simpler dosing, stronger pain relief, fewer restrictions, or lower cost. Failed programs will remove weaker candidates and keep the field focused on medicines that show clear value.

 

NaV1.8 Inhibitors Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.06 Billion
Revenue Forecast in 2032	USD 2.35 Billion
Overall Growth Rate	CAGR of 68.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Suzetrigine/Journavx, LTG-001, LTG-305, STC-004, VX-993, Grünenthal NaV1.8 Inhibitor, Other Investigational NaV1.8 Inhibitors
By Application	Moderate-to-Severe Acute Pain, Postoperative Pain, Painful Diabetic Peripheral Neuropathy, Other Chronic Peripheral Neuropathic Pain
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Pain Clinics, Academic and Clinical Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing demand for non-opioid pain management, FDA approval of first NaV1.8 inhibitor, rising opioid-sparing treatment strategies, expansion of precision pain medicine, increasing investment in peripheral pain-targeting therapies, and potential chronic neuropathic pain applications
Customization Option	Available upon request